Progentos Therapeutics closes USD 65MLn in series A financing
Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, recently announced its launch and the closing of a $65 million series A round. This funding will enable Progentos to advance its MS program through human proof of concept […]
